Brief: Fresenius Announces FDA And EMA Acceptance For Review Of Vedolizumab Biosimilar Candidate
31/07/2026 12:01
BRIEF-Fresenius Announces FDA And EMA Acceptance For Review Of Vedolizumab Biosimilar Candidate July 31 (Reuters) - FRESENIUS SE & CO KGAA FREG.DE:
ANNOUNCES FDA AND EMA ACCEPTANCE FOR REVIEW OF VEDOLIZUMAB BIOSIMILAR CANDIDATE
Source text: ID:nBw5258fga
Further company coverage: FREG.DE
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Fresenius SE & Co. KGaA
See all newsFresenius lifts 2026 expectations after strong Q3 (updated)
Healthcare firm Fresenius Q3 revenue rises on Kabi growth; lifts outlook
Brief: Fresenius Sees FY26 EBIT Margin Above 11.5%
Brief: Fresenius SE Q3 Revenue EUR 5,803 Million
Fresenius signs biosimilars pipeline agreement with WuXi Biologics (updated)